THE COST-EFFECTIVENESS ANALYSIS OF CORONARY ARTERY DISEASE DIAGNOSTIC PARAMETERS IN A CLINICAL LABORATORY SETTING

Author(s)

Guenka Petrova Ivanova, DSc, Assoc. Prof1, Natasa Bogavac-Satnojevic, MD, assistant2, Zorana Jelic-Ivanovic, DSc, Assoc. Prof2, Lidija Memon, MD, pharmacist3, Slavica Spasic, DSc, Assoc. Prof21Faculty of Pharmacy, Medical University, Sofia, Sofia, Bulgaria, Bulgaria; 2 Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia, Serbia and Montenegro; 3 Clinical Chemistry Laboratory, Clinical Centre “Bežanijska kosa”, Belgrade, Serbia, Serbia and Montenegro

OBJECTIVES: The aim of this study was to analyse the cost-effectiveness of consecutive supplementing of the Framingham scoring (FRS) algorithm for coronary artery disease (CAD) risk assessment with apolipoproteins B and A-I (apoA-I and apoB), the apo (a) phenotype, lipoprotein (a), and high sensitivity C-reactive protein (hs-CRP). The perspective of the analysis is the clinical laboratory setting. METHODS: The study is prospective diagnosing of 221 CAD patients and 289 controls. First line testing followed the guidelines for risk assessment based on FRS. Risk factors included in the FRS are: age, total cholesterol, high density cholesterol, systolic blood pressure, treatment for hypertension and cigarette smoking. FRS classifies individuals into those with 10-year risk for CAD of >20% event risk (high risk group), 10-20% event risk (intermediate risk group) and <10% event risk (low risk group). The FRS algorithm was supplemented with apolipoproteins, lipoproteins and hs-CRP and the effectiveness was measured in number needed to diagnose (NND). Total cost of diagnostic procedure was calculated on the basis of the consumed resources for diagnostic tests, labor time, and consumables. To evaluate the additional number needed to be diagnosed for successful CAD risk establishment was performed and incremental cost-effectiveness analysis. RESULTS: A diagnostic strategy employing FRS followed by apoA-I had lowest cost per additionally successfully diagnoses patient than the same strategy followed by hs-CRP in the low (2.63 vs. 24.47 euros) and intermediate risk groups (2.93 vs. 122.86 euros). In the high-risk group the diagnostic strategy employing apo A-I was the cost-effective strategy. It had a lower ICER (-9.14 euros) than the strategy employing hs-CRP (7.16 euros). CONCLUSION: Cost-effectiveness analysis of different diagnostic markers results in improved identification of at-risk patients at a lower health cost for society. In the clinical laboratory setting it is sufficient to determine apoA-I concentration in addition to FRS for CAD risk assessment.

Conference/Value in Health Info

2007-10, ISPOR Europe 2007, Dublin, Ireland

Value in Health, Vol. 10, No. 6 (November/December 2007)

Code

PCV29

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Cardiovascular Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×